Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important next-generation immune checkpoint molecules, playing a similar role as Progra...

Full description

Bibliographic Details
Main Authors: Luisa Chocarro, Ana Bocanegra, Ester Blanco, Leticia Fernández-Rubio, Hugo Arasanz, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Piñeiro-Hermida, Ruth Vera, David Escors, Grazyna Kochan
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cells
Subjects:
opdualag
relatimab
BMS-986016
nivolumab
LAG-3
PD-1
Online Access:https://www.mdpi.com/2073-4409/11/15/2351

Internet

https://www.mdpi.com/2073-4409/11/15/2351

Similar Items